Novacyt Osake

Novacyt Velat/EBITDA

Kokonaisvelka suhteessa EBITDA:han yhtiöstä Novacyt (ALNOV.PA) 14.8.2026 päivämäärällä on −1,59. Edellisenä vuonna Kokonaisvelka suhteessa EBITDA:han oli −1,39 — muutos 14,12 % (matalampi).

Velat/EBITDA

−1,59

YoY

14,12%

Viimeksi päivitetty:

Kokonaisvelka suhteessa EBITDA:han yhtiöstä Novacyt on 2026 −1,59 . Kokonaisvelka suhteessa EBITDA:han yhtiöstä Novacyt oli 2025 −1,39 . Se laskee 14,12% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Novacyt Osakeanalyysi

Mitä Novacyt tekee? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Novacyt osakkeesta

Yhtiön Novacyt Kokonaisvelka suhteessa EBITDA:han on −1,59 vuonna 2026.

Kokonaisvelka suhteessa EBITDA:han yhtiöstä Novacyt muuttui arvosta −1,39 arvoon −1,59, mikä edustaa 14,12 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää Kokonaisvelka suhteessa EBITDA:han Novacyt:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

Velka/EBITDA mittaa kokonaisvelkaa suhteessa tulokseen ennen korkoja, veroja ja poistoja. Se osoittaa, kuinka monella vuodella kaikki velat voitaisiin maksaa takaisin EBITDA:sta.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata Kokonaisvelka suhteessa EBITDA:han:n Novacyt alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Access this data via the Eulerpool API

Vipuvaikutus — Novacyt

Kaikki tunnusluvut — Novacyt